Intrahepatic Sarcomatoid Cholangiocarcinoma

Shalini Malhotra(Addenbrooke's Hospital), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Joanna Wood(Nottingham University Hospitals NHS Trust), T. Mansy(Nottingham University Hospitals NHS Trust), Rajeev Singh(Royal Derby Hospital), Abed Zaitoun(Nottingham University Hospitals NHS Trust)

Journal of Oncology

January 1, 2010

10.1155/2010/701476

Cited by 48

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma

|Nature Genetics|2015|320